No Data
No Data
Progyny, Inc. Announces Details for Its Fourth Quarter and Full Year 2024 Results Report
Breaking Down Progyny: 4 Analysts Share Their Views
Progyny Is Maintained at Buy by B of A Securities
BofA Securities Maintains Progyny(PGNY.US) With Buy Rating, Raises Target Price to $25
Analysts Offer Insights on Healthcare Companies: Progyny (PGNY) and Axsome Therapeutics (AXSM)
Truist Financial Maintains Progyny(PGNY.US) With Hold Rating, Announces Target Price $24